Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487

Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487

Bibliographic Details
Main Authors:	Carroll, P, Maher, K, Foley, R, Stewart, P, Bevan, J, Franklyn, J, Besser, G, Monson, J, Britton, K, Grossman, AB
Format:	Journal article
Published:	2003

Similar Items

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
by: King, C, et al.
Published: (1993)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
by: Ur, E, et al.
Published: (1993)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
by: Kaltsas, G, et al.
Published: (2005)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
by: Kaltsas, G, et al.
Published: (2001)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
by: Valentina Ambrosini, et al.
Published: (2022-02-01)

The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2001)

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics
by: Kushal Chakraborty, et al.
Published: (2023-03-01)

Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.
by: Kaltsas, G, et al.
Published: (1998)

The accuracy of parathyroid gland localization in primary hyperparathyroidism using sestamibi radionuclide imaging.
by: Johnston, L, et al.
Published: (1996)

Targeted radionuclide therapy for neuroendocrine tumours: principles and application.
by: Druce, MR, et al.
Published: (2010)

MRI of pancreatic neuroendocrine tumours.
by: Owen, N, et al.
Published: (2001)

Radiolabeling Technique of Silver Nanoparticles (AgNPs) with Iodine-131 Radionuclide
by: U.N. Sholikhah, et al.
Published: (2020-08-01)

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2004)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
by: Jenkins, P, et al.
Published: (2000)

Radionuclide imaging of neuroendocrine tumors
by: Šaponjski Jelena, et al.
Published: (2020-01-01)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Selective intraarterial radionuclide therapy with yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: Initial experience at a single center
by: Arslan Nuri, et al.
Published: (2011-01-01)

Radiolabeled Dendrimer Coated Nanoparticles for Radionuclide Imaging and Therapy: A Systematic Review
by: Miriam Conte, et al.
Published: (2023-03-01)

Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We Now
by: Mitesh Naik, et al.
Published: (2022-02-01)

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [<sup>64</sup>Cu]Cu-DOTA-TOC
by: Nasim Vahidfar, et al.
Published: (2022-04-01)

RADIONUCLIDE IMAGING AND THERAPY OF NEUROENDOCRINE TUMOURS
by: Shaunak Navalkissoor, et al.
Published: (2015-11-01)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
by: Ur, E, et al.
Published: (1992)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Familial paraganglioma: a novel presentation of a case and response to therapy with radiolabelled MIBG.
by: Lawrence, J, et al.
Published: (2004)

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
by: Kaltsas, G, et al.
Published: (2002)

Ytrium 90 as a radionuclide for therapy
by: Alejandro Alberti Ramírez
Published: (2012-07-01)

Radionuclide imaging and therapy in patients with neuroendocrine tumors
by: Olga D. Baranova, et al.
Published: (2018-03-01)

The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
by: Siddiqi, A, et al.
Published: (2001)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
by: Marianne S. Elston, et al.
Published: (2021-12-01)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
by: Anna Yordanova, et al.
Published: (2020-11-01)

Neuroendocrine Tumours : From Radiomolecular Imaging to Radionuclide Therapy
by: GEORGIOS eLIMOURIS
Published: (2012-02-01)

Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?
by: Vincenzo Cuccurullo, et al.
Published: (2017-10-01)

The diagnosis and medical management of advanced neuroendocrine tumors.
by: Kaltsas, G, et al.
Published: (2004)

The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres
by: Mark A. Westcott, MD, et al.
Published: (2016-10-01)

487 peserta sertai Webinar Antarabangsa
by: Isa, Siti Suriawati, et al.
Published: (2020)

Physiologically Based Pharmacokinetic (PBPK) model for biodistribution of radiolabeled peptides in patients with neuroendocrine tumours
by: Viktor Popov, et al.
Published: (2016-07-01)

Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
by: Korbonits, M, et al.
Published: (1998)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
by: Tiago Nunes da Silva, et al.
Published: (2018-04-01)

Evaluation of carrier added (CA) and no carrier added (NCA) 177Lu radionuclide roles in radiolabeling of peptide groups
by: S. Vosoughi, et al.
Published: (2020-11-01)

I-123 imaging for the prediction of I-131 therapy for recurrent differentiated thyroid cancer, RDTC, when I-131 tracer is negative but raised thyroglobulin, Tg
by: Britton, K, et al.
Published: (1999)